메뉴 건너뛰기




Volumn 194, Issue 4, 2015, Pages 2011-2021

Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CXCL11 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 27; INTERLEUKIN 5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELPHALAN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; SILVER; TUMOR NECROSIS FACTOR ALPHA; ALKYLATING AGENT;

EID: 84922552740     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401894     Document Type: Article
Times cited : (54)

References (56)
  • 6
    • 16844379997 scopus 로고    scopus 로고
    • Immunosuppressive networks in the tumour environment and their therapeutic relevance
    • Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
    • (2005) Nat. Rev. Cancer , vol.5 , pp. 263-274
    • Zou, W.1
  • 8
    • 67349250111 scopus 로고    scopus 로고
    • Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: A role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
    • van der Most, R. G., A. J. Currie, S. Mahendran, A. Prosser, A. Darabi, B. W. Robinson, A. K. Nowak, and R. A. Lake. 2009. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol. Immunother. 58: 1219-1228.
    • (2009) Cancer Immunol. Immunother. , vol.58 , pp. 1219-1228
    • Van Der Most, R.G.1    Currie, A.J.2    Mahendran, S.3    Prosser, A.4    Darabi, A.5    Robinson, B.W.6    Nowak, A.K.7    Lake, R.A.8
  • 10
    • 65549141834 scopus 로고    scopus 로고
    • The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor mi-croenvironment for immune-based cancer therapies
    • Ozao-Choy, J., G. Ma, J. Kao, G. X. Wang, M. Meseck, M. Sung, M. Schwartz, C. M. Divino, R Y. Pan, and S. H. Chen. 2009. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor mi-croenvironment for immune-based cancer therapies. Cancer Res. 69: 2514-2522.
    • (2009) Cancer Res. , vol.69 , pp. 2514-2522
    • Ozao-Choy, J.1    Ma, G.2    Kao, J.3    Wang, G.X.4    Meseck, M.5    Sung, M.6    Schwartz, M.7    Divino, C.M.8    Pan, R.Y.9    Chen, S.H.10
  • 11
    • 84892686102 scopus 로고    scopus 로고
    • Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer
    • Alizadeh, D., M. Trad, N. T. Hanke, C. B. Larmonier, N. Janikashvili, B. Bonnotte, E. Katsanis, and N. Larmonier. 2014. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 74: 104-118.
    • (2014) Cancer Res. , vol.74 , pp. 104-118
    • Alizadeh, D.1    Trad, M.2    Hanke, N.T.3    Larmonier, C.B.4    Janikashvili, N.5    Bonnotte, B.6    Katsanis, E.7    Larmonier, N.8
  • 12
  • 13
    • 77956680680 scopus 로고    scopus 로고
    • A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers
    • Kodumudi, K. N., K. Woan, D. L. Gilvary, E. Sahakian, S. Wei, and J. Y. Djeu. 2010. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16: 4583-4594.
    • (2010) Clin. Cancer Res. , vol.16 , pp. 4583-4594
    • Kodumudi, K.N.1    Woan, K.2    Gilvary, D.L.3    Sahakian, E.4    Wei, S.5    Djeu, J.Y.6
  • 15
    • 84880733312 scopus 로고    scopus 로고
    • Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology
    • Kalos, M., and C. H. June. 2013. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39: 49-60.
    • (2013) Immunity , vol.39 , pp. 49-60
    • Kalos, M.1    June, C.H.2
  • 16
    • 84890147150 scopus 로고    scopus 로고
    • Exploiting the curative potential of adoptive T-cell therapy for cancer
    • Hinrichs, C. S., and S. A. Rosenberg. 2014. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 257: 56-71.
    • (2014) Immunol. Rev. , vol.257 , pp. 56-71
    • Hinrichs, C.S.1    Rosenberg, S.A.2
  • 17
    • 0021826670 scopus 로고
    • +,2 T cells. Tumor eradication does not require participation of cytotoxic T cells
    • +,2 T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161: 1122-1134.
    • (1985) J. Exp. Med. , vol.161 , pp. 1122-1134
    • Greenberg, P.D.1    Kern, D.E.2    Cheever, M.A.3
  • 21
    • 0032473562 scopus 로고    scopus 로고
    • Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
    • Ossendorp, F, E. Mengedé, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187: 693-702.
    • (1998) J. Exp. Med. , vol.187 , pp. 693-702
    • Ossendorp, F.1    Mengedé, E.2    Camps, M.3    Filius, R.4    Melief, C.J.5
  • 25
    • 34249677872 scopus 로고    scopus 로고
    • + TEs provides intratumoral TE proliferation and synergistic antitumor response
    • + TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood 109: 4865-4876.
    • (2007) Blood , vol.109 , pp. 4865-4876
    • Wang, L.X.1    Shu, S.2    Disis, M.L.3    Plautz, G.E.4
  • 27
    • 68049118838 scopus 로고    scopus 로고
    • Immunity to murine prostatic tumors: Continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells
    • Shafer-Weaver, K. A., S. K. Watkins, M. J. Anderson, L. J. Draper, A. Malyguine, W. G. Alvord, N. M. Greenberg, and A. A. Hurwitz. 2009. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res. 69: 6256-6264.
    • (2009) Cancer Res. , vol.69 , pp. 6256-6264
    • Shafer-Weaver, K.A.1    Watkins, S.K.2    Anderson, M.J.3    Draper, L.J.4    Malyguine, A.5    Alvord, W.G.6    Greenberg, N.M.7    Hurwitz, A.A.8
  • 32
    • 77950600201 scopus 로고    scopus 로고
    • + T-cell differentiation and restores an activated polyfunctional helper phenotype
    • + T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 115: 2397-2406.
    • (2010) Blood , vol.115 , pp. 2397-2406
    • Ding, Z.C.1    Blazar, B.R.2    Mellor, A.L.3    Munn, D.H.4    Zhou, G.5
  • 35
    • 0032170052 scopus 로고    scopus 로고
    • Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation
    • Guillaume, T., D. B. Rubinstein, and M. Symann. 1998. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92: 1471-1490.
    • (1998) Blood , vol.92 , pp. 1471-1490
    • Guillaume, T.1    Rubinstein, D.B.2    Symann, M.3
  • 37
    • 84863858208 scopus 로고    scopus 로고
    • Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide
    • Salem, M. L., A. A. Al-Khami, S. A. El-Nagaar, A. A. Zidan, I. M. Al-Sharkawi, C. Marcela Diaz-Montero, and D. J. Cole. 2012. Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. Cell. Immunol. 276: 67-74.
    • (2012) Cell. Immunol. , vol.276 , pp. 67-74
    • Salem, M.L.1    Al-Khami, A.A.2    El-Nagaar, S.A.3    Zidan, A.A.4    Al-Sharkawi, I.M.5    Marcela Diaz-Montero, C.6    Cole, D.J.7
  • 38
    • 77949889975 scopus 로고    scopus 로고
    • Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a flt3 ligand-dependent expansion of dendritic cells
    • Salem, M. L., A. A. Al-Khami, S. A. El-Naggar, C. M. Dfaz-Montero, Y Chen, and D. J. Cole. 2010. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J. Immunol. 184: 1737-1747.
    • (2010) J. Immunol. , vol.184 , pp. 1737-1747
    • Salem, M.L.1    Al-Khami, A.A.2    El-Naggar, S.A.3    Dfaz-Montero, C.M.4    Chen, Y.5    Cole, D.J.6
  • 39
    • 77958489808 scopus 로고    scopus 로고
    • Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces
    • Sonnenberg, G. F, L. A. Fouser, and D. Artis. 2010. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv. Immunol. 107: 1-29.
    • (2010) Adv. Immunol. , vol.107 , pp. 1-29
    • Sonnenberg, G.F.1    Fouser, L.A.2    Artis, D.3
  • 40
    • 0026643596 scopus 로고
    • Interleukin-5, eosinophils, and disease
    • Sanderson, C. J. 1992. Interleukin-5, eosinophils, and disease. Blood 79: 3101-3109.
    • (1992) Blood , vol.79 , pp. 3101-3109
    • Sanderson, C.J.1
  • 41
    • 84867905099 scopus 로고    scopus 로고
    • IL-1 family members IL-18 and IL-33 up-regulate the inflammatory potential of differentiated human thl and th2 cultures
    • Blom, L., and L. K. Poulsen. 2012. IL-1 family members IL-18 and IL-33 up-regulate the inflammatory potential of differentiated human Thl and Th2 cultures. J. Immunol. 189: 4331-4337.
    • (2012) J. Immunol. , vol.189 , pp. 4331-4337
    • Blom, L.1    Poulsen, L.K.2
  • 43
    • 0020593560 scopus 로고
    • Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth
    • Ben-Efraim, S., R. C. Bocian, M. B. Mokyr, and S. Dray. 1983. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol. Immunother. 15: 101-107.
    • (1983) Cancer Immunol. Immunother. , vol.15 , pp. 101-107
    • Ben-Efraim, S.1    Bocian, R.C.2    Mokyr, M.B.3    Dray, S.4
  • 45
    • 15044338886 scopus 로고    scopus 로고
    • Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation
    • Lindemann, M., P. Schuett, T Moritz, H. D. Ottinger, B. Opalka, S. Seeber, M. R. Nowrousian, and H. Grosse-Wilde. 2005. Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation. Leukemia 19: 490-492.
    • (2005) Leukemia , vol.19 , pp. 490-492
    • Lindemann, M.1    Schuett, P.2    Moritz, T.3    Ottinger, H.D.4    Opalka, B.5    Seeber, S.6    Nowrousian, M.R.7    Grosse-Wilde, H.8
  • 46
    • 0032519429 scopus 로고    scopus 로고
    • Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor
    • Mokyr, M. B., T. V Kalinichenko, L. Gorelik, and J. A. Bluestone. 1998. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. J. Immunol. 160: 1866-1874.
    • (1998) J. Immunol. , vol.160 , pp. 1866-1874
    • Mokyr, M.B.1    Kalinichenko, T.V.2    Gorelik, L.3    Bluestone, J.A.4
  • 47
    • 0034660469 scopus 로고    scopus 로고
    • Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells
    • Sojka, D. K., M. Donepudi, J. A. Bluestone, and M. B. Mokyr. 2000. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J. Immunol. 164: 6230-6236.
    • (2000) J. Immunol. , vol.164 , pp. 6230-6236
    • Sojka, D.K.1    Donepudi, M.2    Bluestone, J.A.3    Mokyr, M.B.4
  • 48
    • 0033917007 scopus 로고    scopus 로고
    • B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells
    • Sojka, D. K., R. N. La Motte, and M. B. Mokyr. 2000. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells. Cancer Immunol. Immunother. 49: 10-22.
    • (2000) Cancer Immunol. Immunother. , vol.49 , pp. 10-22
    • Sojka, D.K.1    La Motte, R.N.2    Mokyr, M.B.3
  • 49
    • 0037382989 scopus 로고    scopus 로고
    • Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells
    • Donepudi, M., V M. Jovasevic, P. Raychaudhuri, and M. B. Mokyr. 2003. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Cancer Immunol. Immunother. 52: 162-170.
    • (2003) Cancer Immunol. Immunother. , vol.52 , pp. 162-170
    • Donepudi, M.1    Jovasevic, V.M.2    Raychaudhuri, P.3    Mokyr, M.B.4
  • 52
    • 76249097336 scopus 로고    scopus 로고
    • Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodeple-tion in patients with multiple myeloma: A window for adoptive immunotherapy
    • Condomines, M., J. L. Veyrune, M. Larroque, P. Quittet, P. Latry, C. Lugagne, C. Hertogh, T. Kanouni, J. F Rossi, and B. Klein. 2010. Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodeple-tion in patients with multiple myeloma: a window for adoptive immunotherapy. J. Immunol. 184: 1079-1084.
    • (2010) J. Immunol. , vol.184 , pp. 1079-1084
    • Condomines, M.1    Veyrune, J.L.2    Larroque, M.3    Quittet, P.4    Latry, P.5    Lugagne, C.6    Hertogh, C.7    Kanouni, T.8    Rossi, J.F.9    Klein, B.10
  • 54
    • 67650360757 scopus 로고    scopus 로고
    • Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells
    • Rapoport, A. P., E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H. B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, et al. 2009. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin. Cancer Res. 15: 4499-4507.
    • (2009) Clin. Cancer Res. , vol.15 , pp. 4499-4507
    • Rapoport, A.P.1    Stadtmauer, E.A.2    Aqui, N.3    Vogl, D.4    Chew, A.5    Fang, H.B.6    Janofsky, S.7    Yager, K.8    Veloso, E.9    Zheng, Z.10
  • 55
    • 84903990337 scopus 로고    scopus 로고
    • Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis
    • Ding, Z. C, X. Lu, M. Yu, H. Lemos, L. Huang, P. Chandler, K. Liu, M. Walters, A. Krasinski, M. Mack, et al. 2014. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Res. 74: 3441-3453.
    • (2014) Cancer Res. , vol.74 , pp. 3441-3453
    • Ding, Z.C.1    Lu, X.2    Yu, M.3    Lemos, H.4    Huang, L.5    Chandler, P.6    Liu, K.7    Walters, M.8    Krasinski, A.9    Mack, M.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.